For the second week in a row , a drug developer is going public via a special purpose acquisition company (SPAC), the blank-check …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
EGFR-mutant lung cancer is an ADC battleground, with China leading the charge October 26, 2026
Lilly’s music-loving, intense lead dealmaker knows what he wants October 26, 2026
Roche taps Zymeworks in up to $813M deal for preclinical T cell engager October 23, 2026
Merck and Moderna's cancer vaccine data were 'a triumph of science.' And now, the work begins
BioNTech, DualityBio ponder next steps for HER2 ADC after 'modest' breast cancer results
Roche takes victory lap with lung cancer pill's win over Amgen, Bristol Myers
Swiss biotech Windward Bio files for Nasdaq IPO to fund China-derived assets and in-house R&D
Bristol Myers reveals death in MS CAR-T trial, has answer for safety signal in lupus trial
Source link







